One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
Riccardo Proietti MD, Gregory Y.H. Lip MD,Â
doi : 10.1111/dom.14818
The missing heritability in type 1 diabetes
Haipeng Pang MD, Jian Lin MD, Shuoming Luo MD, Gan Huang MS, Xia Li MD, Zhiguo Xie PhD, Zhiguang Zhou MD,Â
doi : 10.1111/dom.14777
Type 1 diabetes (T1D) is a complex autoimmune disease characterized by an absolute deficiency of insulin. It affects more than 20 million people worldwide and imposes an enormous financial burden on patients.
C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective
Ernesto Maddaloni MD, Geremia B. Bolli MD, Brian M. Frier MD, Randie R. Little PhD, Richard D. Leslie MD, Paolo Pozzilli MD, Raffaela Buzzetti MD,Â
doi : 10.1111/dom.14785
Impaired beta-cell function is a recognized cornerstone of diabetes pathophysiology. Estimates of insulin secretory capacity are useful to inform clinical practice, helping to classify types of diabetes, complication risk stratification and to guide treatment decisions.
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Chao Li, Jie Yu, Carinna Hockham, Vlado Perkovic, Brendon L. Neuen, Sunil V. Badve, Lauren Houston, Vivian Y. J. Lee, Jennifer Y. Barraclough, Robert A. Fletcher, Kenneth W. Mahaffey, Hiddo J. L. Heerspink, Christopher P. Cannon, Bruce Neal, Clare Arnott,Â
doi : 10.1111/dom.14772
To assess the effects of canagliflozin on the incidence of atrial fibrillation/atrial flutter (AF/AFL) and other key cardiorenal outcomes in a pooled analysis of the CANVAS and CREDENCE trials.
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease
Benjamin P. Larkin PhD, Long T. Nguyen PhD, Miao Hou PhD, Sarah J. Glastras PhD, Hui Chen MD, Alen Faiz PhD, Jason Chen PhD, Rosy Wang PhD, Carol A. Pollock PhD, Sonia Saad PhD,Â
doi : 10.1111/dom.14778
To determine, using a mouse model of obesity, whether low-dose hydralazine prevents obesity-related chronic kidney disease (CKD).
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
Taha Sen, Akihiko Koshino, Bruce Neal, Maarten J. Bijlsma, Clare Arnott, Jingwei Li, Michael K. Hansen, Joachim H. Ix, Hiddo J. L. Heerspink,Â
doi : 10.1111/dom.14779
To test the hypothesis that the reduction in urinary kidney injury molecule-1 (KIM-1) observed with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin is mediated through its effects on urine albumin to creatinine ratio (UACR) and monocyte chemoattractant protein-1 (MCP-1) by assessing the proportion of the effect of canagliflozin on KIM-1 that is mediated through its effects on MCP-1 and UACR in patients with type 2 diabetes and albuminuric kidney disease.
Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial
Qi Pan MD, Yijun Li MD, Hailong Wan BMed, Junfen Wang BMed, Binhua Xu MMed, Guoping Wang MMed, Chengxia Jiang BMed, Li Liang BMed, Wei Feng MMed, Jingcheng Liu PhD, Ting Wang MSc, Xia Zhang MD, Nan Cui MD, Yiming Mu MD, Lixin Guo MD, for the BEYOND V Study Investigators ,Â
doi : 10.1111/dom.14780
To compare the efficacy and safety of basal insulin glargine 100 units/ml (Gla) + 2-3 oral antihyperglycaemic drugs (OADs) with twice-daily premixed insulin aspart 70/30 (Asp30) + metformin (MET) after short-term intensive insulin therapy in adults with type 2 diabetes in China.
Dual-hormone artificial pancreas for glucose control in type 1 diabetes: A meta-analysis
Baoqi Zeng MD, Hao Jia MD, Le Gao PhD, Qingqing Yang PhD, Kai Yu PhD, Feng Sun PhD,Â
doi : 10.1111/dom.14781
To evaluate the efficacy and safety of a dual-hormone artificial pancreas (DH) in type 1 diabetes.
Glycaemic measures for 8914 adult FreeStyle Libre users during routine care, segmented by age group and observed changes during the COVID-19 pandemic
Pratik Choudhary MD, Kalvin Kao BS, Timothy C. Dunn PhD, Laura Brandner BS, Gerry Rayman MD, Emma G. Wilmot PhD,Â
doi : 10.1111/dom.14782
To evaluate the impact of the stay-at-home policy on different glucose metrics for time in range (%TIR 3.9-10 mmol/L), time below range (%TBR < 3.9 mmol/L) and time above range (%TAR > 10 mmol/L) for UK adult FreeStyle Libre (FSL) users within four defined age groups and on observed changes during the coronavirus disease 2019 (COVID-19) pandemic.
Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial
Wiebe M. C. Top MD, Philippe Lehert PhD, Casper G. Schalkwijk PhD, Coen D. A. Stehouwer MD, Adriaan Kooy MD,Â
doi : 10.1111/dom.14784
To study the effect of metformin on plasma levels of arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), indicators of the nitric oxide pathway.
Effectiveness, safety and treatment adherence of biosimilar follow-on insulin in diabetes management
Timothy T. Pham PhD, Xiaoxue Chen MPH, John Barron PhD, Richard Hart MD, Jacob Abarca PharmD, Andrea DeVries PhD,Â
doi : 10.1111/dom.14786
To assess the change in HbA1c after initiation of biosimilar follow-on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2 diabetes. We also compared treatment adherence, safety events and costs at 1 year after initiation of insulin.
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
Irene Hramiak MD, Hertzel C. Gerstein MD, Lawrence A. Leiter MD, Jean-François Yale MD, Harpreet S. Bajaj MD, John Stewart MSc, Marie-Josée Toutounji BPharm, Stewart B. Harris MD,Â
doi : 10.1111/dom.14787
To compare the efficacy and safety of a simple daily titration algorithm compared with a weekly dose adjustment of iGlarLixi in people with type 2 diabetes.
Obesity-associated metabolites in relation to type 2 diabetes risk: A prospective nested case-control study of the CARRS cohort
Mohammed K. Ali MD, M. Masood Kadir MPH, Unjali P. Gujral PhD, Syeda Sadia Fatima MD, Romaina Iqbal PhD, Yan V. Sun PhD, K. M. Venkat Narayan MD, Shafqat Ahmad PhD,Â
doi : 10.1111/dom.14788
To determine whether obesity-associated metabolites are associated with type 2 diabetes (T2DM) risk among South Asians.
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
Nicolai J. Wewer Albrechtsen MD, Andreas Møller MSc, Christoffer Martinussen MD, Lise L. Gluud DMSci, Elias B. Rashu, Michael M. Richter MD, Peter Plomgaard MD, Jens P. Goetze, Sasha Kjeldsen MSc, Lasse Holst Hansen MSc, Finn Gustafsson DMSci, Carolyn F. Deacon DMSci, Jens J. Holst DMSci, Sten Madsbad DMSci, Kirstine N. Bojsen-Møller MD,Â
doi : 10.1111/dom.14789
Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 diabetes. We previously reported that sacubitril/valsartan combined with a dipeptidyl peptidase-4 inhibitor increases active glucagon-like peptide-1 (GLP-1) in healthy individuals. We now hypothesized that administration of sacubitril/valsartan with or without a dipeptidyl peptidase-4 inhibitor would lower postprandial glucose concentrations (primary outcome) in patients with type 2 diabetes via increased active GLP-1.
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes
Christine R. Andreasen MD, Andreas Andersen MD, Per G. Hagelqvist MD, Julius V. Lauritsen MS, Peter G. Jørgensen MD, Susanne Engberg MD, Jens Faber MD, Bolette Hartmann PhD, Ulrik Pedersen-Bjergaard MD, Filip K. Knop MD, Tina Vilsbøll MD,Â
doi : 10.1111/dom.14790
To investigate echocardiographic changes during acute hypoglycaemia followed by recovery to hyperglycaemia or euglycaemia in patients with type 1 diabetes.
The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass
Bo Liu, Inmaculada Ruz-Maldonado, Klaudia Toczyska, Oladapo E. Olaniru, Mohammed Gulrez Zariwala, David Hopkins, Min Zhao, Shanta J. Persaud,Â
doi : 10.1111/dom.14791
This study investigated whether therapeutically relevant concentrations of fluoxetine, which have been shown to reduce plasma glucose and glycated haemoglobin independent of changes in food intake and body weight, regulate beta-cell function and improve glucose homeostasis.
Long-term clinical outcomes of oral antidiabetic drugs as fixed-dose combinations: A nationwide retrospective cohort study
Sang-Jun Cho MSc, In-Sun Oh PhD, Han Eol Jeong MPH, Young Min Cho MD, Yul Hwangbo MD, Oriana Hoi Yun Yu MD, Ju-Young Shin PhD,Â
doi : 10.1111/dom.14792
To compare treatment patterns and clinical outcomes of single-pill fixed-dose combination (FDC) and two-pill combination (TPC) therapies using real-world data.
Forecasting postbariatric hypoglycaemia in patients after Roux-en-Y gastric bypass using model-based algorithms fed by continuous glucose monitoring data: A proof-of-concept study
Francesco Prendin MSc, Giacomo Cappon PhD, Afroditi Tripyla MD, David Herzig PhD, Lia Bally PhD, Andrea Facchinetti PhD,Â
doi : 10.1111/dom.14783
Postbariatric hypoglycaemia (PBH) is an increasingly recognized late complication of bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB).1, 2 Between 20% and 80% of patients after RYGB may develop the condition, which is characterized by postprandial hypoglycaemic episodes with increased severity after ingestion of carbohydrates with a high glycaemic impact.
